The efficacy and safety of mepolizumab in severe eosinophilic asthma: a literature review
B.A. Chernyak, I.I. Vorzheva
Irkutsk State Medical Academy of Postgraduate Education – Branch of the Russian Medical Academy of Continuous Professional Education, Irkutsk, Russia
The review presents modern ideas about severe eosinophilic bronchial asthma (SEBA); in this disease, a central role in the regulation and increased activation of eosinophils is played by the cytokines associated with this asthma phenotype, including interleukin-5. In this regard, in recent years, targeted therapy for SEBA using anti-interleukin-5 drugs, including mepolizumab, has been actively developing. A number of clinical studies carried out in accordance with the modern requirements of evidence-based medicine have demonstrated that a decrease in the level of eosinophilia that develops during treatment with mepolizumab in patients with SEBA is accompanied by a decrease in the frequency of exacerbations, improved control of the disease and lung function, and improved quality of life. The clinical effect of mepolizumab is independent of atopic status and eosinophilia level. Given the frequent combination of SEBA with polypous rhinosinusitis, data on the clinical efficacy of mepolizumab in this comorbid pathology, which significantly aggravate the condition of patients, deserve attention. The results of the studies analyzed and generalized in the review allow the authors to conclude that the wider introduction of mepolizumab for the treatment of SEBA patients is feasible.
Keywords: severe eosinophilic bronchial asthma, interleukin-5, mepolizumab
About the Autors
Corresponding author: Boris A. Chernyak, MD, Professor, Head of the Department of Clinical Allergology and Pulmonology, Irkutsk State Medical Academy of Postgraduate Education – Branch of the Russian Medical Academy of Continuous Professional Education, Irkutsk, Russia; e-mail: email@example.com
Address: 100, Yubileiny microdistrict, Irkutsk 664049, Russian Federation